MX2019009407A - Nuevas composiciones de vacuna que comprenden oligonucleotidos inmunoestimulantes. - Google Patents

Nuevas composiciones de vacuna que comprenden oligonucleotidos inmunoestimulantes.

Info

Publication number
MX2019009407A
MX2019009407A MX2019009407A MX2019009407A MX2019009407A MX 2019009407 A MX2019009407 A MX 2019009407A MX 2019009407 A MX2019009407 A MX 2019009407A MX 2019009407 A MX2019009407 A MX 2019009407A MX 2019009407 A MX2019009407 A MX 2019009407A
Authority
MX
Mexico
Prior art keywords
vaccine compositions
antigen
immunostimulatory oligonucleotides
novel vaccine
component
Prior art date
Application number
MX2019009407A
Other languages
English (en)
Inventor
Joseph Dominowski Paul
K Rai Sharath
Mary Sly Laurel
Patrick Cook Corey
Mwangi Duncan
L Foss Dennis
Lee Krebs Richard
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of MX2019009407A publication Critical patent/MX2019009407A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/27—Equine rhinopneumonitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invencion proporciona una composicion de vacuna que comprende un componente de antigeno y un componente de adyuvante, en la que el componente de adyuvante comprende un oligonucleotido inmunoestimulante de clase P y o bien una combinacion de una saponina y un esterol; o una fase oleosa que comprende un aceite y, opcionalmente, uno o mas emulsionantes, comprendiendo dicha fase oleosa el 2-20 % v / v de la composicion de vacuna, en la que dicho componente de antigeno es un antigeno del EHV o un antigeno de Leishmania.
MX2019009407A 2013-05-14 2015-11-13 Nuevas composiciones de vacuna que comprenden oligonucleotidos inmunoestimulantes. MX2019009407A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361823189P 2013-05-14 2013-05-14

Publications (1)

Publication Number Publication Date
MX2019009407A true MX2019009407A (es) 2019-09-26

Family

ID=50897961

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015015758A MX367268B (es) 2013-05-14 2014-05-12 Nuevas composiciones de vacuna que comprenden oligonucleotidos inmunoestimulantes.
MX2019009407A MX2019009407A (es) 2013-05-14 2015-11-13 Nuevas composiciones de vacuna que comprenden oligonucleotidos inmunoestimulantes.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015015758A MX367268B (es) 2013-05-14 2014-05-12 Nuevas composiciones de vacuna que comprenden oligonucleotidos inmunoestimulantes.

Country Status (20)

Country Link
EP (2) EP2996719B1 (es)
JP (2) JP6505084B2 (es)
CN (2) CN108079290A (es)
AR (1) AR096277A1 (es)
AU (2) AU2014265649B2 (es)
BR (1) BR112015028748A2 (es)
CA (2) CA3027289A1 (es)
DK (1) DK3542819T3 (es)
ES (2) ES2894138T3 (es)
HK (1) HK1219426A1 (es)
HR (1) HRP20211452T1 (es)
HU (1) HUE056040T2 (es)
LT (1) LT3542819T (es)
MX (2) MX367268B (es)
PL (1) PL3542819T3 (es)
PT (2) PT2996719T (es)
RU (1) RU2627447C2 (es)
SI (1) SI3542819T1 (es)
WO (1) WO2014186291A1 (es)
ZA (1) ZA201507774B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62015B1 (sr) * 2015-07-20 2021-07-30 Zoetis Services Llc Kompozicije lipozomalnog adjuvansa
US10456459B2 (en) * 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions
BE1023538B1 (fr) * 2016-04-22 2017-04-26 Sil'innov Scrl Silices mésoporeuses et leur procédé de synthèse

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7904021A (nl) * 1979-05-22 1980-04-29 Gist Brocades Nv Gecombineerd vaccin en werkwijze voor het bereiden van dit gecombineerd vaccin tegen door adeno achtige virussen veroorzaakte eiproduktiedalingen en door reo virus veroorzaakte ziekteverschijnselen.
US6803041B2 (en) * 2001-03-20 2004-10-12 Boehringer Ingelheim Vetmedica, Inc. Equine herpesvirus vaccine
EP2283858A3 (en) * 2001-07-27 2011-03-23 Wyeth LLC West Nile Vaccine
AU2003247880B2 (en) * 2002-07-03 2010-09-02 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
US20070166800A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
KR101251707B1 (ko) * 2006-09-27 2013-04-11 콜리 파마슈티칼 게엠베하 면역 자극 활성이 증강된 소수성 Ｔ 유사체를 함유하는 ＣｐＧ 올리고뉴클레오티드 유사체
BRPI0717219B8 (pt) * 2006-10-12 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, e, uso de uma composição imunogênica
CN103025351B (zh) * 2010-05-28 2016-08-24 佐蒂斯比利时股份有限公司 包含胆固醇和作为唯一的佐剂-载剂分子的cpg的疫苗
US20120114688A1 (en) * 2010-11-08 2012-05-10 Infectious Disease Research Institute Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis

Also Published As

Publication number Publication date
SI3542819T1 (sl) 2021-11-30
CN108079290A (zh) 2018-05-29
AR096277A1 (es) 2015-12-16
PL3542819T3 (pl) 2022-01-10
RU2015146752A (ru) 2017-06-20
EP3542819A1 (en) 2019-09-25
CA3027289A1 (en) 2014-11-20
AU2017232231A1 (en) 2017-10-12
ZA201507774B (en) 2017-09-27
JP2016518446A (ja) 2016-06-23
HK1219426A1 (zh) 2017-04-07
RU2627447C2 (ru) 2017-08-08
CN105263518B (zh) 2018-03-20
HUE056040T2 (hu) 2022-01-28
NZ713360A (en) 2021-06-25
AU2014265649B2 (en) 2017-10-19
HRP20211452T1 (hr) 2021-12-24
EP2996719A1 (en) 2016-03-23
BR112015028748A2 (pt) 2017-09-19
LT3542819T (lt) 2021-11-10
ES2742325T3 (es) 2020-02-13
EP2996719B1 (en) 2019-06-26
PT3542819T (pt) 2021-10-14
JP6505084B2 (ja) 2019-04-24
JP2019108328A (ja) 2019-07-04
CA2911938C (en) 2019-07-16
PT2996719T (pt) 2019-09-03
AU2014265649A1 (en) 2015-11-12
CA2911938A1 (en) 2014-11-20
DK3542819T3 (da) 2021-09-20
WO2014186291A1 (en) 2014-11-20
CN105263518A (zh) 2016-01-20
EP3542819B1 (en) 2021-08-18
MX367268B (es) 2019-08-12
MX2015015758A (es) 2016-03-16
ES2894138T3 (es) 2022-02-11

Similar Documents

Publication Publication Date Title
HK1257816A1 (zh) 包含綴合的莢膜糖抗原的免疫原性組合物及其試劑盒和用途
HUS2200035I1 (hu) Konjugált burokszaccharid antigéneket tartalmazó immunogén készítmények és alkalmazásaik
MX2021005619A (es) Coadyuvantes basados en aceite.
EP2762155A3 (en) Vaccine Composition
CR20160502A (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso
EP3669891A4 (en) VACCINE ADJUVANS WITH LIPOPEPTIDE-INSERTED LIPOSOME AS THE ACTIVE SUBSTANCE AND USE OF IT
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
MX2023013020A (es) Procedimiento para fabricar un adyuvante.
MX2019004690A (es) Constructos de anticuerpos.
SG11202007676RA (en) Immunogenic composition comprising staphylococcal antigens
PH12019501569A1 (en) Universal influenza vaccine compositions
MX2021000951A (es) Composición que contiene vacuna contra la influenza.
EP3603619A4 (en) VACCINAL ADJUVANT FORMULATION
IN2014CN03454A (es)
EP3442546A4 (en) ANTI-OBESITY MICROBIOTE COMPOSITIONS AND METHODS OF PREPARATION AND USES THEREOF
MX2019009407A (es) Nuevas composiciones de vacuna que comprenden oligonucleotidos inmunoestimulantes.
WO2018138681A9 (en) Hemagglutinin-specific antibodies and uses thereof
BR112019023742A2 (pt) anticorpos anti-trkb
BR112016016672A2 (pt) Uso de uma composição
GB2562241B (en) Vaccine compositions
MX2015015428A (es) Eliminacion de riesgo de narcolepsia en vacunas contra influenza.
EP3615005A4 (en) VACCINATION COMPOSITIONS AND METHODS
IT201700100170A1 (it) Busta ad evidenza di manomissione, procedimento per la realizzazine di detta busta ed uso della stessa per il contenimento di prodotti
MX2021009718A (es) Composicion de adyuvante para una vacuna.
PH12018500146A1 (en) Liposomal adjuvant compositions